|Bid||69.36 x 1400|
|Ask||72.24 x 900|
|Day's Range||71.13 - 73.54|
|52 Week Range||60.23 - 140.11|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 30, 2018 - Aug 3, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||81.29|
Roy A. Whitfield, Nektar Therapeutics (NKTR) director, and former chairman and chief executive of Incyte (INCY), bought $290,200 in Nektar shares last week, buying as the biotech's shares show weakness. ...
Highlights include new Phase 2 data for baricitinib in systemic lupus erythematosus INDIANAPOLIS , June 11, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today it will present new data ...
NEW YORK , June 5, 2018 /PRNewswire/ -- ARMO BioSciences, Inc. (ARMO) Lifshitz & Miller announces investigation into possible breaches of fiduciary duties in connection with the proposed sale of ARMO ...
Eli Lilly (LLY) and its partner Incyte announce approval of their arthritis drug, Olumiant, in the United States. The drug will be available at two-fifth of the price of leading RA drugs.
Eli Lilly & Co's rheumatoid arthritis treatment was approved by U.S. regulators on Friday with a far more restrictive label than expected and the drugmaker said the drug would be priced at half the cost ...
The approval of OLUMIANT is based on the Phase 3 clinical trial program that demonstrated efficacy for difficult to treat patients1 INDIANAPOLIS , June 1, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 31) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) (Piper Jaffray initiated ...
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Wall Street analysts expect the company to see a 40.9% rise in revenue to $459.8 million in Q2 2018. Incyte’s stock price has fallen nearly 51.7% over the last 12 months and nearly 29.6% in 2018 year-to-date. Wall Street analysts’ recommendations show a 12-month target price of $81.0 per share compared to its price of $66.67 per share on May 24.
Incyte (INCY) has a well-established distribution network in the United States and sells its products Jakafi and Iclusig in the United States through its own network.
Incyte’s (INCY) oncology drug Jakafi (ruxolitinib) is approved for the treatment of myelofibrosis and polycythemia vera, two rare types of blood cancer.
Incyte’s (INCY) product portfolio includes targeted therapies and immuno-therapies for oncology and non-oncology diseases. At present, Incyte’s revenue includes the product sales of Jakafi and Iclusig, royalty revenue, and milestone and contract revenues.
Incyte (INCY) reported revenue of $382.3 million in Q1 2018, a marginal decline compared to $384.1 million in Q1 2017. Its revenue in the quarter was driven by increased demand for the drugs Jakafi and Iclusig as well as growth in royalty revenue.
Incyte’s (INCY) consolidated revenue rose to $328.3 million in Q1 2018 compared to $384.1 million in Q1 2017. In Q1 2018, the company reported net revenue of -$2.6 million compared to $29.1 million in Q1 2017.
Incyte Corporation (INCY) is a biopharmaceutical company with headquarters in Wilmington, Delaware. Incyte’s business includes the discovery, development, and commercialization of various products to cater to unmet medical needs in oncology and the treatment of other diseases.
Some recent clinical trial results have tempered enthusiasm in the highflying cancer immunotherapy sector. & Co.’s Keytruda unshackle the immune system to help it fight tumors. Corp. and Merck said Phase 3 studies comparing melanoma patients receiving Keytruda, plus the Incyte drug epacadostat, didn’t perform better than cases where Keytruda was used alone.
Biotech shares put up a lackadaisical show this week, as reflected by the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ). With earnings season winding down, FDA decisions and data presentations ...
In the first quarter, Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% year-over-year to $144.4 million from $115.8 million. Analysts expect Ionis’s top line to rise ~30.2% to ~$135.7 million in the second quarter. The chart below shows analysts’ recommendations for Ionis stock over the last year.
Ionis Pharmaceuticals (IONS), a leading therapeutics company, develops and markets drugs for life-threatening diseases. The chart below compares Ionis’s revenue and EPS since Q1 2017. In the first quarter, Ionis’s revenue rose ~24.7% year-over-year to $144.4 million from $115.8 million.
On CNBC's "Mad Money Lightning Round" , Jim Cramer advised his viewer to hold his long position in Sirius XM Holdings Inc (NASDAQ: SIRI ). He has been recommending the stock since $4 and he is ...